Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema

Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

J Fernando Arevalo, Juan G. Sanchez, Jans Fromow-Guerra, Lihteh Wu, Maria H. Berrocal, Michel E. Farah, Jose Cardillo, Francisco J. Rodríguez

Research output: Contribution to journalArticle

Abstract

Background: To report the 12-month anatomic and ETDRS best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin®) (1.25 mg or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the two different doses of intravitreal bevacizumab (IVB) utilized was made. Methods: We reviewed the clinical records of 82 consecutive patients (101 eyes) with DDME in this interventional retrospective multicenter study. All patients with a minimum follow-up of 12 months (mean 57.6±8.4 weeks) were included in this analysis. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Results: The mean age of our patients was 59.7±9.3 years. The mean number of IVB injections per eye was three (range: one to six injections) at a mean interval of 14.1±10.5 weeks. In the 1.25 mg group at 1 month BCVA improved from 20/190, logMAR=0.97 to 20/85, logMAR 0.62, a difference that was statistically significant (p=0.0001). This improvement was maintained throughout the 3-, 6-, and 12-month follow-up. The mean final BCVA at 12 months was 20/76, logMAR=0.58 (p

Original languageEnglish (US)
Pages (from-to)735-743
Number of pages9
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume247
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Macular Edema
Retina
Visual Acuity
Intravitreal Injections
Fluorescein Angiography
Optical Coherence Tomography
Multicenter Studies
Retrospective Studies
Bevacizumab
Injections

Keywords

  • Avastin
  • Bevacizumab
  • Diffuse diabetic macular edema
  • Intravitreal injections
  • OCT
  • Primary treatment

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema : Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. / Arevalo, J Fernando; Sanchez, Juan G.; Fromow-Guerra, Jans; Wu, Lihteh; Berrocal, Maria H.; Farah, Michel E.; Cardillo, Jose; Rodríguez, Francisco J.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 247, No. 6, 06.2009, p. 735-743.

Research output: Contribution to journalArticle

@article{f0372c99823949d7ac9bece250d148c4,
title = "Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up",
abstract = "Background: To report the 12-month anatomic and ETDRS best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin{\circledR}) (1.25 mg or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the two different doses of intravitreal bevacizumab (IVB) utilized was made. Methods: We reviewed the clinical records of 82 consecutive patients (101 eyes) with DDME in this interventional retrospective multicenter study. All patients with a minimum follow-up of 12 months (mean 57.6±8.4 weeks) were included in this analysis. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Results: The mean age of our patients was 59.7±9.3 years. The mean number of IVB injections per eye was three (range: one to six injections) at a mean interval of 14.1±10.5 weeks. In the 1.25 mg group at 1 month BCVA improved from 20/190, logMAR=0.97 to 20/85, logMAR 0.62, a difference that was statistically significant (p=0.0001). This improvement was maintained throughout the 3-, 6-, and 12-month follow-up. The mean final BCVA at 12 months was 20/76, logMAR=0.58 (p",
keywords = "Avastin, Bevacizumab, Diffuse diabetic macular edema, Intravitreal injections, OCT, Primary treatment",
author = "Arevalo, {J Fernando} and Sanchez, {Juan G.} and Jans Fromow-Guerra and Lihteh Wu and Berrocal, {Maria H.} and Farah, {Michel E.} and Jose Cardillo and Rodr{\'i}guez, {Francisco J.}",
year = "2009",
month = "6",
doi = "10.1007/s00417-008-1034-x",
language = "English (US)",
volume = "247",
pages = "735--743",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0721-832X",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema

T2 - Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

AU - Arevalo, J Fernando

AU - Sanchez, Juan G.

AU - Fromow-Guerra, Jans

AU - Wu, Lihteh

AU - Berrocal, Maria H.

AU - Farah, Michel E.

AU - Cardillo, Jose

AU - Rodríguez, Francisco J.

PY - 2009/6

Y1 - 2009/6

N2 - Background: To report the 12-month anatomic and ETDRS best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin®) (1.25 mg or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the two different doses of intravitreal bevacizumab (IVB) utilized was made. Methods: We reviewed the clinical records of 82 consecutive patients (101 eyes) with DDME in this interventional retrospective multicenter study. All patients with a minimum follow-up of 12 months (mean 57.6±8.4 weeks) were included in this analysis. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Results: The mean age of our patients was 59.7±9.3 years. The mean number of IVB injections per eye was three (range: one to six injections) at a mean interval of 14.1±10.5 weeks. In the 1.25 mg group at 1 month BCVA improved from 20/190, logMAR=0.97 to 20/85, logMAR 0.62, a difference that was statistically significant (p=0.0001). This improvement was maintained throughout the 3-, 6-, and 12-month follow-up. The mean final BCVA at 12 months was 20/76, logMAR=0.58 (p

AB - Background: To report the 12-month anatomic and ETDRS best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin®) (1.25 mg or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the two different doses of intravitreal bevacizumab (IVB) utilized was made. Methods: We reviewed the clinical records of 82 consecutive patients (101 eyes) with DDME in this interventional retrospective multicenter study. All patients with a minimum follow-up of 12 months (mean 57.6±8.4 weeks) were included in this analysis. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Results: The mean age of our patients was 59.7±9.3 years. The mean number of IVB injections per eye was three (range: one to six injections) at a mean interval of 14.1±10.5 weeks. In the 1.25 mg group at 1 month BCVA improved from 20/190, logMAR=0.97 to 20/85, logMAR 0.62, a difference that was statistically significant (p=0.0001). This improvement was maintained throughout the 3-, 6-, and 12-month follow-up. The mean final BCVA at 12 months was 20/76, logMAR=0.58 (p

KW - Avastin

KW - Bevacizumab

KW - Diffuse diabetic macular edema

KW - Intravitreal injections

KW - OCT

KW - Primary treatment

UR - http://www.scopus.com/inward/record.url?scp=67349157689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349157689&partnerID=8YFLogxK

U2 - 10.1007/s00417-008-1034-x

DO - 10.1007/s00417-008-1034-x

M3 - Article

VL - 247

SP - 735

EP - 743

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0721-832X

IS - 6

ER -